DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Medtech (369)

Contrast Agents and Radiopharmaceuticals | US | 2015 | Market Analysis

The US market for contrast agents and radiopharmaceuticals will be limited by reimbursement restrictions and lower dosing; nonetheless, growth in the large radiopharmaceutical market and favorable demographics will result in a modest expansion of the market through 2023.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals across a 10-year period.

Questions Answered in This Report:

  • New products have recently entered the contrast agent and radiopharmaceutical market in the US, with more are expected to enter before 2023.

    How will the launch of new products influence ASPs over the forecast period?

    What strategies can existing competitors adopt to respond to heightened competitive pressure?

  • Global fluctuations in the supply of Mo-99the key isotope in the production of Tc for use in most SPECT procedureswill continue to impact the market going forward.

    To what extent will supply limitations affect revenue growth in the US SPECT radiopharmaceutical market?

    What strategies will vendors and facilities employ in response to supply fluctuations?

  • The ASP per procedure is set to decline for contrast-enhanced procedures over the forecast period.

    What are the key factors causing this trend?

    Which markets will be most heavily affected by this decline and why?

    What role do competitive dynamics play in causing this trend? How are companies reacting to this trend?

Scope:

Geographies Covered: US

Procedures and Products Covered: DRG's analysis uses the following breakdown of procedures and products in the market:

Product Type

Radiopharmaceuticals

Product Type

SPECT

PET

CT and X-Ray Contrast Agents*

Product Type

CT

Cardiovascular X-Ray

Conventional X-Ray

MRI Contrast Agents**

Ultrasound Contrast Agents***

Notes: (1) *Only injectable iodinated contrast agents are included; barium-based agents used as bowel markers for these modalities are excluded. (2) **Only gadolinium-based MRI contrast agents are included. (3) ***Installed base values are not included. The market model only includes ultrasound contrast agents used for echocardiography and excludes all other ultrasound procedures.

Market Forecast Features: Based on primary research with industry professionals, DRG uses its proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, ASPs, market values, and the installed base over a 10-year period (2013–2023).

Competitive Analysis: DRG provides a detailed analysis of the competitive landscape and market shares for leading competitors.